Image pharmaphorum Editor News EU approves Ipsen's Cabometyx in first line kidney cancer Drug looks set to become core part of Ipsen's cancer offering White Papers Sponsored Medical meetings and what HCPs want The healthcare professional (HCP) meeting landscape is evolving, but even as it adjusts to the demands of the digital age new research has shown that face-to-face meetings retain a prominent place News FDA approves Pfizer's epoetin biosimilar Retacrit Epoetin alfa biosimilars available in EU for more than a decade News Novo expands type 1 diabetes R&D Company will also focus on serious chronic diseases Load more results
News EU approves Ipsen's Cabometyx in first line kidney cancer Drug looks set to become core part of Ipsen's cancer offering
White Papers Sponsored Medical meetings and what HCPs want The healthcare professional (HCP) meeting landscape is evolving, but even as it adjusts to the demands of the digital age new research has shown that face-to-face meetings retain a prominent place
News FDA approves Pfizer's epoetin biosimilar Retacrit Epoetin alfa biosimilars available in EU for more than a decade
News Novo Nordisk to cut GLP-1 prices in tough US market Novo Nordisk has turned to pricing as a means to shore up its position in the increasingly competitive market for GLP-1 agonist therapies in the US.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
